ONCIN: Oncoinvent presents 3Q company update in live webcast
2026-10-28 07:04:14
Oslo, Norway, 28 October 2026 - Oncoinvent ASA (ONCIN), a biotech company
developing a receptor-independent alpha radiopharmaceutical to eradicate cancer
cells in the abdominal cavity after surgery with a single, targeted dose, is
hosting a live webcast at 10:00 AM CET today, Wednesday, 28 October 2026.
- Presenters: CEO Øystein Soug, CFO Ramzi Amri, CMO Zuzana Jirakova Trnkova
- Time: 10:00am CET
- Webcast link: https://qcnl.tv/p/8awn9AmyNjOd67OuY7TwRQ
Highlights:
- Recruited 16 patients into the ovarian Phase 2 trial, having a total of 71
patients by end 3Q
- Added one more clinical site to Oncoinvent's Phase 2 trial; 11 clinical
sites now recruiting
- Published Normal tissue dosimetry results in Journal of Nuclear Medicine
- Presented three abstracts at EANM and ESMO
- Completed successful private placement raising gross proceeds of NOK 148.5
million
- Appointed Dr Zuzana Jirakova Trnkova as Chief Medical Offier
The presentation material and the recording of the webcast will be made
available at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by
quarterly business updates to keep stakeholders informed and ensure ongoing
transparency.
For further information, please contact:
Oncoinvent
Oystein Soug, Chief Executive Officer
IR@oncoinvent.com
Optimum Strategic Communications
Zoe Bolt, Katherine Bliss, Henry Williams
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2H2026 (safety) and 1H2027 (early efficacy).
With cost-effective manufacturing, blockbuster potential, active pharma
partnership momentum, plus strong endorsements from leading experts, Oncoinvent
is built for scale and commercial success, and is set to become the new standard
for post-surgical cancer care. The Company was founded by the originators of
Algeta and Xofigo (acquired by Bayer).
ical cancer care. The Company was founded by the originators of\
Algeta and Xofigo (acquired by Bayer).\